Cost-Effectiveness of Vonoprazan-Based and Rifabutin-Based vs Other Regimens as First-Line Treatment of Helicobacter pylori Infection in the United States.
The American journal of gastroenterology（2023）
摘要
H. pylori infection eradication with vonoprazan triple therapy would provide the greatest net health and monetary benefit from the perspective of US healthcare payers.
更多查看译文
关键词
Helicobacter pylori, cost-effectiveness analysis, vonoprazan dual therapy, vonoprazan triple therapy, rifabutin triple therapy
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要